Diabetes on a cardiovascular ward: Adherence to current recommendations

Southern Medical Journal

Volumn 97, Issue 11, 2004, Pages 1031-1037

  Bethel, M Angelyn ^b   Alexander, John ^b   Lane, Jim ^b   Barkauskas, Christina ^b   Feinglos, Mark N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Diabetes mellitus; Hemoglobin A1c; Standards of care

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; HUMAN; INCIDENCE; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; VISUAL SYSTEM EXAMINATION;

ACADEMIC MEDICAL CENTERS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; GUIDELINE ADHERENCE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; QUALITY ASSURANCE, HEALTH CARE; RISK FACTORS; VASCULAR DISEASES;

EID: 8744296020     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000140853.71806.31     Document Type: Review

References (32)

1. Hogan P, Dall T, Nikolov P. American Diabetes Association: economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-932.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
4. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UK-PDS 35): prospective observational study. BMJ 2000;321:405-412.
6. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S33-S50.
7. Beckles GL, Engelgau MM, Narayan KM, et al. Population-based assessment of the level of care among adults with diabetes in the US. Diabetes Care 1998;21:1432-1438.
8. Harris MI. Medical care for patients with diabetes: epidemiologic aspects. Ann Intern Med 1996;124:117-122.
9. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-2000.
10. Janes GR. Ambulatory medical care for diabetes, in Harris MI, Cowie CC, Ster MP, et al (eds): Diabetes in America. 2nd ed. National Institutes of Health, Publication No. 95-1468, Bethesda, MD, 1995, pp 541-551.
11. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000;23:390-404.
12. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996;124:164-169.
13. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127:788-795.
14. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000;283:889-896.
15. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-426.
16. Richardson WC, Berwick DM, Bisgard JC, et al: To err is human: building a safer health system. Institute of Medicine Report 1999; November. Retrieved February 19, 2004 from http://www.nap.edu/books/ 0309068371/html
17. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
18. Fertig BJ, Simmons DA, Martin DB. Therapy for diabetes, in Harris MI, Cowie CC, Ster MP, et al (eds): Diabetes in America. 2nd ed. National Institutes of Health. Publication No. 95-1468, Bethesda, MD, 1995, pp 519-540.
19. Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care 2001;24:1411-1415.
20. Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with Type 2 diabetes: a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-488.
21. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003;290:81-85.
22. Wysowski DK, Armstrong G, Govemale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care 2003;26:1852-1855.
23. Meinert CL, Knatterud GL, Prout TE, et al: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, II: mortality results. Diabetes 1970;19(Suppl 2):789-830.
24. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
25. Deutsch E, Berger M, Kussmaul WG, et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation 1990;82:2044-2051.
26. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994;24:1133-1142.
27. Riddle MC. Editorial: sulfonylureas differ in effects on ischemic preconditioning: is it time to retire glyburide? J Clin Endocrinol Metab 2003;88:528-530.
28. Lee T-M, Chou T-F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88:531-537.
29. Van den Berghe G, Wouters M, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-1367.
30. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
31. Koproski J, Pretto Z, Poretsky L. Effects of an intervention by a diabetes team in hospitalized patients with diabetes. Diabetes Care 1997;20:1553-1555.
32. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27:553-591.